Search This Blog

Monday, November 25, 2019

Arrowhead Pharma up 5% after Medicines Co. sale

Baird upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to Outperform with $70 price target (40% upside), noting Novartis’ purchase of The Medicines Company means a re-evaluation of ARWR’s RNAi platform.
Shares are up 5.3% to $49.20 premarket.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)